超声辅助碳纳米颗粒混悬液与双示踪剂引导早期乳腺癌前哨淋巴结活检:III期随机临床试验
该前瞻性、非劣效性III期随机对照试验纳入330例早期乳腺癌患者,比较超声辅助碳纳米颗粒混悬液(CNS)与CNS联合吲哚菁绿(ICG)双示踪剂引导前哨淋巴结活检(SLNB)的可行性及诊断性能。主要终点为前哨淋巴结识别率,超声辅助CNS组为94.5%(95%CI 90.9-98.0),双示踪剂组为95.8%(95%CI 92.7-98.9),差异-1.3%(95%CI -5.9至3.3),低于预设非劣效界值6%(非劣效性P=0.024),证实超声辅助CNS引导SLNB不劣于双示踪剂引导。
要点
- 超声辅助CNS引导SLNB的前哨淋巴结识别率不劣于CNS联合ICG双示踪剂引导
- 两组转移淋巴结率、检出前哨淋巴结中位数及手术时间均无显著差异
- 新辅助化疗后亚组中两组前哨淋巴结识别率亦相近
核心结论
- 在早期乳腺癌患者中,超声辅助CNS引导SLNB的诊断性能不劣于CNS联合ICG双示踪剂引导。
研究设计与样本
- 前瞻性、非劣效性III期随机对照试验,纳入330例早期乳腺癌患者(cN0或新辅助化疗后降期为cN0的cN1),1:1随机分为超声辅助CNS组(163例)和CNS联合ICG双示踪剂组(167例)。
主要发现
- 前哨淋巴结识别率超声辅助CNS组为94.5%(95%CI 90.9-98.0),双示踪剂组为95.8%(95%CI 92.7-98.9),差异-1.3%(95%CI -5.9至3.3),低于预设非劣效界值6%(非劣效性P=0.024)。
- 转移淋巴结率两组分别为30.5%和24.4%(P=0.222),检出前哨淋巴结中位数均为3枚(范围1-7 vs 1-8,P=0.181),手术时间分别为7.53(标准差2.77)分钟和7.63(标准差3.27)分钟(P=0.316)。
- 新辅助治疗亚组中,前哨淋巴结识别率超声辅助CNS组为91.7%(95%CI 82.2-100),双示踪剂组为90.7%(95%CI 81.7-99.7)。
临床怎么用
- 超声辅助CNS引导可作为早期乳腺癌SLNB的一种示踪选择,其识别率与双示踪剂引导相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Appropriate tracing methods for sentinel lymph node biopsy (SLNB) play a key role in accurate axillary staging. This prospective, non-inferiority, phase III RCT compared the feasibility and diagnostic performance of ultrasound-assisted carbon nanoparticle suspension (CNS) mapping with dual tracer-guided SLNB in patients with early breast cancer. METHODS: Eligible patients had primary breast cancer without nodal involvement (cN0), or had clinically positive lymph nodes (cN1) that were downstaged to cN0 after neoadjuvant chemotherapy. Patients were randomly assigned (1 : 1) to undergo either ultrasound-assisted CNS sentinel lymph node (SLN) mapping (UC group) or dual tracer-guided mapping with CNS plus indocyanine green (ICG) (GC group). The primary endpoint was the SLN identification rate. RESULTS: Between 1 December 2019 and 30 April 2021, 330 patients were assigned randomly to the UC (163 patients) or GC (167 patients) group. The SLN identification rate was 94.5 (95 per cent c.i. 90.9 to 98.0) per cent in the UC group and 95.8 (92.7 to 98.9) per cent in the GC group. The observed difference of -1.3 (-5.9 to 3.3) per cent was lower than the prespecified non-inferiority margin of 6 per cent (Pnon-inferiority = 0.024). No significant difference was observed in metastatic node rate (30.5 versus 24.4 per cent; P = 0.222), median number of SLNs harvested (3 (range 1-7) versus 3 (1-8); P = 0.181), or duration of surgery (mean(s.d.) 7.53(2.77) versus 7.63(3.27) min; P = 0.316) between the groups. Among the subgroup of patients who had undergone neoadjuvant treatment, the SLN identification rate was 91.7 (82.2 to 100) per cent in the UC group and 90.7 (81.7 to 99.7) per cent in the GC group. CONCLUSION: The diagnostic performance of ultrasound-assisted CNS mapping was non-inferior to that of dual tracer-guided SLN mapping with CNS plus ICG in patients with early breast cancer. REGISTRATION NUMBER: NCT04951245 (http://www.clinicaltrials.gov).
引用
- Zhang L, Cheng M, Lin Y, et al. Ultrasound-assisted carbon nanoparticle suspension mapping versus dual tracer-guided sentinel lymph node biopsy in patients with early breast cancer (ultraCars): phase III randomized clinical trial. Br J Surg. 2022. PMID: 36074703. doi:10.1093/bjs/znac311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。